Evidence map›Paper›PMID 40537756›Full record

ArticleMalaria journal2025

In vitro activity and in vivo efficacy of omadacycline against Plasmodium species.

Michael S Madejczyk, Susan E Leed, Karl Kudyba, Alison Roth, Monica L Martin, Patricia Lee, Diane Anastasiou, Jessica V Pierce, Alisa W Serio, Diana Caridha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael S MadejczykExperimental Therapeutics Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA. michael.s.madejczyk.civ@health.mil.
Susan E LeedExperimental Therapeutics Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
Karl KudybaExperimental Therapeutics Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
Alison RothExperimental Therapeutics Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
Monica L MartinExperimental Therapeutics Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
Patricia LeeExperimental Therapeutics Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
Diane AnastasiouParatek Pharmaceuticals Inc, King of Prussia, PA, 19406, USA.
Jessica V PierceParatek Pharmaceuticals Inc, King of Prussia, PA, 19406, USA.
Alisa W SerioParatek Pharmaceuticals Inc, King of Prussia, PA, 19406, USA.
Diana CaridhaExperimental Therapeutics Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDoxycycline is currently the only tetracycline-class antibiotic recommended for malaria prophylaxis. Omadacycline, a semisynthetic aminomethylcycline approved for treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, has a well-established safety profile. This study evaluated the in vitro activity of omadacycline against Plasmodium falciparum and Plasmodium cynomolgi and its in vivo efficacy against Plasmodium berghei in experimental malaria models to assess its potential as an antimalarial drug.

methodsFluorescence-based assays were used to assess the in vitro blood and liver stage activity of omadacycline and doxycycline against P. falciparum and P. cynomolgi laboratory clones. In vivo liver and early-stage blood stage efficacy were evaluated in a murine model of P. berghei infection, utilizing in vivo imaging of luciferase-expressing P. berghei (ANKA strain) sporozoites in female albino C57Bl/6 mice. Parasitaemia was monitored by flow cytometry for up to 30 days post-infection.

resultsOmadacycline demonstrated comparable in vitro activity to doxycycline against both drug-sensitive and drug-resistant P. falciparum clones, while doxycycline showed reduced activity against two drug-resistant clones. Notably, omadacycline exhibited superior anti-schizont activity in the P. cynomolgi liver stage assay. In the P. berghei murine model, omadacycline was efficacious in both liver and early blood stages compared to the untreated control group, and demonstrated improved survival compared to doxycycline.

conclusionsOmadacycline demonstrated enhanced antimalarial efficacy over doxycycline in vitro in liver stage activity and in overcoming resistance in the blood stage, and in survival in an in vivo model of P. berghei infection. These findings support further investigation of omadacycline as a potential candidate for malaria prophylaxis and treatment.

Indexed as

AntimalarialsMalariaPlasmodiumPlasmodium bergheiPlasmodium falciparumTetracyclinesAnimalsDisease Models, AnimalDoxycyclineFemaleLiverMiceMice, Inbred C57BLParasitemiaTreatment OutcomeAntimalarialsDoxycyclineomadacyclineTetracyclinesAntimalarial drugsDoxycyclineIn vivo imaging technologyOmadacyclineParasitemiaPlasmodium bergheiPlasmodium cynomolgiPlasmodium falciparum

Identifiers

PMID40537756
PMCPMC12177959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.